不朽情缘网站

One of Joint Biosciences' lead products, OVV-01, is a recombinant vesicular stomatitis virus (VSV) engineered to express the NY-ESO-1 tumor-associated antigen. It is currently being investigated  in a Phase 2 clinical trial for the treatment of patients with soft tissue sarcoma. We are actively conducting clinical trials to obtain regulatory approval and in order to expedite broader patient access to OVV-01. At this stage of development, we believe participation in our clinical trials is the most appropriate pathway to access OVV-01. Information about our clinical trials, including eligibility criteria and trial locations, will be available at ClinicalTrials.gov.

Joint Biosciences acknowledges the interest of patients in accessing OVV-01 outside of clinical trials, particularly for life-threatening conditions prior to regulatory approval. However, we currently do not offer Expanded Access Programs (EAPs) for OVV-01 but will continue to evaluate this policy based on emerging data from ongoing and future clinical trials.

2025/2/25